呼吸频率-氧合(ROX)指数预测合并与不合并COVID-19的急性低氧性呼吸衰竭患者高流量鼻导管失败
该回顾性分析纳入2020年10月至2022年4月在急诊科接受HFNC治疗的448例急性低氧性呼吸衰竭患者,其中78例(17.4%)确诊COVID-19。不合并COVID-19组与合并COVID-19组的HFNC失败率无显著差异(29.5% vs. 33.3%,p=0.498)。ROX指数在不合并COVID-19组各时间点中位数均高于合并COVID-19组;ROC曲线下面积在合并COVID-19组(0.73-0.83)总体高于不合并COVID-19组(0.62-0.75)。不合并COVID-19组预测HFNC失败的最佳时机为4小时,合并COVID-19组在1至6小时表现一致;最佳截断值分别为6.48和5.79。作者认为,高于既往ICU研究报道的ROX阈值提示对非ICU收治患者需仔细监测并建立新阈值。
要点
- 急诊科448例急性低氧性呼吸衰竭HFNC患者中,不合并COVID-19组HFNC失败率29.5%,合并COVID-19组33.3%,两组无显著差异(p=0.498)。
- ROX指数预测HFNC失败的ROC曲线下面积:不合并COVID-19组0.62-0.75,合并COVID-19组0.73-0.83,合并COVID-19组总体更高。
- 不合并COVID-19组ROX指数预测HFNC失败的最佳时机为4小时,合并COVID-19组在1至6小时表现一致。
- 预测HFNC失败的最佳ROX截断值:不合并COVID-19组6.48,合并COVID-19组5.79,均高于既往涉及ICU患者研究报道的阈值。
- 不合并COVID-19组ROX指数中位数在所有时间点均高于合并COVID-19组。
适用人群与场景
- 2020年10月至2022年4月在急诊科因急性低氧性呼吸衰竭接受HFNC治疗的患者,共448例,其中78例(17.4%)确诊COVID-19。
诊断标准与关键阈值
- ROX指数于HFNC放置后1、2、4、6、12、24小时计算。
- HFNC失败定义为72小时内需要后续插管或死亡。
- 预测HFNC失败的最佳ROX截断值:不合并COVID-19组6.48,合并COVID-19组5.79。
研究设计与关键结果
- 研究类型:回顾性分析;人群:急诊科急性低氧性呼吸衰竭接受HFNC治疗的患者448例,其中COVID-19确诊78例(17.4%)。
- 主要终点:HFNC失败率在不合并COVID-19组为29.5%,合并COVID-19组为33.3%,两组无显著差异(p=0.498)。
- ROX指数中位数在不合并COVID-19组所有时间点均高于合并COVID-19组。
- ROX指数预测HFNC失败的ROC曲线下面积:不合并COVID-19组0.62-0.75,合并COVID-19组0.73-0.83。
- ROX指数预测HFNC失败的最佳时机:不合并COVID-19组为4小时,合并COVID-19组在1至6小时表现一致。
- 最佳截断值:不合并COVID-19组6.48,合并COVID-19组5.79。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ROX指数在急诊科急性低氧性呼吸衰竭伴或不伴COVID-19患者中对HFNC失败具有可接受的判别力。
- 作者认为,高于既往涉及ICU患者研究报道的ROX阈值提示对非ICU收治患者需仔细监测并建立新阈值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The predictive value of the respiratory rate‑oxygenation (ROX) index for a high-flow nasal cannula (HFNC) in patients with COVID-19 with acute hypoxemic respiratory failure (AHRF) may differ from patients without COVID-19 with AHRF, but these patients have not yet been compared. We compared the diagnostic accuracy of the ROX index for HFNC failure in patients with AHRF with and without COVID-19 during acute emergency department (ED) visits.
METHODS: We performed a retrospective analysis of patients with AHRF treated with an HFNC in an ED between October 2020 and April 2022. The ROX index was calculated at 1, 2, 4, 6, 12, and 24 h after HFNC placement. The primary outcome was the failure of the HFNC, which was defined as the need for subsequent intubation or death within 72 h. A receiver operating characteristic (ROC) curve was used to evaluate discriminative power of the ROX index for HFNC failure.
RESULTS: Among 448 patients with AHRF treated with an HFNC in an ED, 78 (17.4%) patients were confirmed to have COVID-19. There was no significant difference in the HFNC failure rates between the non-COVID-19 and COVID-19 groups (29.5% vs. 33.3%, p = 0.498). The median ROX index was higher in the non-COVID-19 group than in the COVID-19 group at all time points. The prognostic power of the ROX index for HFNC failure as evaluated by the area under the ROC curve was generally higher in the COVID-19 group (0.73-0.83) than the non-COVID-19 group (0.62-0.75). The timing of the highest prognostic value of the ROX index for HFNC failure was at 4 h for the non-COVID-19 group, whereas in the COVID-19 group, its performance remained consistent from 1 h to 6 h. The optimal cutoff values were 6.48 and 5.79 for the non-COVID-19 and COVID-19 groups, respectively.
CONCLUSIONS: The ROX index had an acceptable discriminative power for predicting HFNC failure in patients with AHRF with and without COVID-19 in the ED. However, the higher ROX index thresholds than those in previous publications involving intensive care unit (ICU) patients suggest the need for careful monitoring and establishment of a new threshold for patients admitted outside the ICU.
参考来源
- Kwon H, Ha SW, Kim B, et al. Respiratory rate‑oxygenation (ROX) index for predicting high-flow nasal cannula failure in patients with and without COVID-19. Am J Emerg Med. 2023. PMID: 37913715. doi:10.1016/j.ajem.2023.09.036
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。